Develops experimental cancer medicines, including atebimetinib and envometinib, for patients with solid tumors.
10-K for FY2025, filed Mar 6, 2026We are a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive. We are developing andโฆView โ
Our lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of mitogen-activated protein kinaseโฆView โ
Our development pipeline also includes our additional clinical-stage product candidate envometinib (IMM-6-415) and other early-stageโฆView โ
10-Q for Q3 FY2026, filed Oct 29, 2026
โ$24.2MView โ
8-K, filed Jun 1, 2026
In mid-2026, dosing the first patient in a pivotal Phase 3 clinical trial of atebimetinib in combination with mGnP in first-line pancreaticโฆView โ
From services to drug development
The older report describes computational biology partnerships alongside internally developed drug programs. The latest report says the company ceased its computational biology services business and has focused exclusively on its own research and development programs.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 6, 2026These different types of biochemical and 3D tumor growth assays each provide us with unique information about the molecular mechanisms ofโฆView โ
Loading...